23andMe: The Path to $2.6B
23andMe, the consumer genetics and research company, has formed a partnership with GlaxoSmithKline (GSK) after receiving a $300 million investment from the pharmaceutical giant. Best known for their direct-to-consumer saliva based tests, the partnership will give GSK access to 23andMe's genetic database. The company's new valuation spits out to approximately $2.6 billion after the new round of funding.
23andMe: The Path to $2.6B

Calculations are based on shares outstanding. Explain

Companies analyzed in the Path to IPO are chosen on the basis of interest to the investing public and are not necessarily those in which transactions have been completed on the EquityZen platform. An investment through EquityZen is not an investment in a primary funding round; accordingly it is unlikely that an investment through EquityZen will perform similarly to the primary funding rounds highlighted in the Path to IPO. Most private companies are not successful enough to have an IPO, and many successful private companies may elect to not have an IPO. Investing in a private company through EquityZen may result in a partial or complete loss of your investment.

Other Companies

If you're interested in 23andMe, you may also be interested in these other companies

Emulate
Organs-on-Chips Company
Founded
'13
Genome Medical
Genome Medical is a telegenomics technology and services company allowing access to genomic-based medicine.
Founded
'16
LunaDNA
The first and largest health and DNA research platform owned by its community.
Founded
'
Odoo
Integrated business applications
Founded
'05
Switch Communications
Phone service provider for Google Apps
Founded
'11